Top Markets
#1 MowCat MowCat +26.72%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +17.90%
#3 Versatize Coin Versatize Coin +16.67%
#4 OriginTrail OriginTrail +12.28%
#5 Pons Pons +11.65%
#6 Wrapped NXM Wrapped NXM +10.43%
#7 QuantixAI QuantixAI +9.67%
#8 Collector Crypt Collector Crypt +9.04%
#9 StonkBroker StonkBroker +8.80%
#10 Siren Siren +8.07%
Coin of the day
MowCat MowCat
Settings
Language
ENGLISH
Currency
USD
Theme
Great Novel Therapeutics Biotech & Medicals Great Novel Therapeutics Biotech & Medicals

Great Novel Therapeutics Biotech & Medicals

7427
Rank in Stocks #20756
Great Novel Therapeutics Biotech & Medicals specializes in crafting... Great Novel Therapeutics Biotech & Medicals specializes in crafting pharmaceutical solutions to combat advanced and treatment-resistant cancers. Their primary focus lies in the realm of cancer immunotherapy, encompassing the creation of compounds such as tumor microenvironment regulators, epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors. The company was previously known as GNT Biotech & Medicals Corporation. Established in 2013, its headquarters are situated in Taipei City, Taiwan.
Share Price
$2.32
Market Cap
$122.09M
Change (1 day)
0.00%
Change (1 year)
109.59%
Country
TW
Trade Great Novel Therapeutics Biotech & Medicals (7427)

Category

Healthcare
Revenue for Great Novel Therapeutics Biotech & Medicals (7427)
Revenue in Aug 2026 TTM: 0
According to Great Novel Therapeutics Biotech & Medicals latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Great Novel Therapeutics Biotech & Medicals from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH